On December 29, 2025, Northwest Biotherapeutics, Inc. held its annual meeting where stockholders approved the election of Pat Sarma to the Board and an increase in authorized shares from 1.7 billion to 2.6 billion. The meeting featured a quorum with over 1.19 billion shares voting, representing 77.4% of the total combined voting power.